A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Exclusion Criteria

• •1. Subjects with any form of Parkinsonism other than idiopathic Parkinson's disease.
• •2. Subjects currently experiencing motor fluctuations (end of dose wearing off), dyskinesias, or significant postural hypotension.
• •3. Subjects treated with l-dopa, anticholinergics, amantadine, MAO inhibitors, COMT inhibitors, tricyclic antidepressants, and / or SSRI and SNRI antidepressants.
• •4. Subjects with a history of psychosis, either previously or currently, or a score ≥ 3 on item 2 or 3 of the UPDRS Part I.
• •5. Subjects with evidence of dementia or cognitive dysfunction.
• •6. Subjects with current diagnosis of substance abuse or history of alcohol or drug abuse in the past three months.
• •7. Subjects with current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including hypertension that is not well controlled, asthma, chronic obstructive pulmonary disease, and Type I diabetes.
• •8. Subjects with a concomitant disease likely to alter absorption, metabolism or elimination of the study drug.
• •9. Female subjects must be neither pregnant nor lactating.
• •10. Subjects with hypersensitivity or contraindications to MAO-B inhibitors.
• •11. Subjects with a neoplastic disorder, which is either currently active or has been in remission for less than one year.
• •12. Subjects with second- or third-degree atrio-ventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within three months of the screening visit, or significant ECG abnormality, including QTc ≥ 450 msec (males) or ≥ 470 msec (females), where QTc is based on Bazett's correction method.
• •13. Subjects with a history or a current diagnosis of human immunodeficiency virus infection, or tests positive for Hepatitis B surface antigen, tests positive for Hepatitis B core antibody, but negative for Hepatitis B surface antibody, or tests positive for Hepatitis C antibodies.
• •14. Subjects who have participated in a previous clinical trial with safinamide, have participated in a previous clinical trial within 30 days of entry into the study, or have received treatment with any investigational compound within thirty days or five half-lives, whichever is longer, prior to screening.
• •15. Subjects with any abnormality that the investigator deems to be clinically relevant.
• •16. Legal incapacity or limited legal capacity
• •17. Other significant disease that in the Investigator's opinion would exclude the subject from the trial.
• •18. Treatment with a drug that has hepatotoxic potential within 4 weeks, or received radiation therapy or a drug with cytotoxic potential within one year prior to the screening visit.
• •19. Ophthalmologic history including any of the following conditions: albino subjects, family history of hereditary retinal disease, progressive and/or severe diminution of visual acuity, retinitis pigmentosa, retinal pigmentation due to any cause, any active retinopathy or ocular inflammation, or diabetic retinopathy.